• POST-TEST QUESTIONNAIRE

    Sunday, September 7th, 2025 | Palm Beach, Florida

  • Clinical Update for Non-Cystic Fibrosis Bronchiectasis: Strategies to Manage Exacerbations and Lung Function
    Supported by an independent education grant from Insmed

  • 1. Which of the following should be considerations when evaluating a patient for bronchiectasis?*
  • 2. Which of the following medications should be considered for treatment of this patients slow respiratory decline?*

  • Update on Long-Acting Nebulizers for Guideline-Based Maintenance Treatments for Patients with COPD
    Supported by an independent education grant from Viatris Specialty LLC

  • Therapeutic Update on COPD with Type 2 Inflammation
    Supported by an independent education grant from GSK

  • 3. What proportion of patients who experience a severe COPD exacerbation are re-hospitalized within 30 days?*
  • 4. Which of the following should be the initial pharmacologic treatment plan for a patient diagnosed with COPD who is in GOLD group E?*
  • 5. In the Phase 3 MATINEE trial, treatment with Mepolizumab was associated with reductions in COPD exacerbations of:*

  • EVALUATION FORM

  • AcademicCME appreciates your opinions to help assist us in the evaluation of the effectiveness of this activity and to identify your ongoing educational needs. Learners must complete this evaluation form to receive acknowledgement for completing this activity.

  • What is your license?*
  • What is your specialty?*
  • What is your practice setting?*

  • Please rate the extent to which this activity met the following objectives:

  • Rows
  • Rows
  • Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • Date
     - -

  • Attestation: This activity is certified for a maximum of 1.5 AMA PRA Category 1 Credits™.

  • Should be Empty: